Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Biofil Chemicals & Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 14 Nov 2026, 5:30 am
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Unaudited ....
Intimation · 14 Nov 2026, 5:30 am
Biofil Chemicals to Consider Q2 Results on 14th Nov'26 Biofil Chemicals and Pharmaceuticals Limited has scheduled a Board of Directors meeting on 14th Nov'26. The board will consider and approve the un-audited financial results of the company for the quarter and half-year ended 30th Sep'26, alongside the Limited Review Report. Additionally, in compliance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed and will reopen 48 hours after the declaration of the financial results.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 14 Nov 2026, 5:30 am
Continuous disclosure of Material event or information for which disclosure as required under sub-clause 7 of Part A Para A Schedule III : 1 .Continuation of directorship of Mr. Ashok ....
Change in Management · 24 Sept 2026, 11:20 pm
Biofil Chemicals Approves Directorship Continuation of Ashok Kumar Ramawat Biofil Chemicals and Pharmaceuticals Limited announced that shareholders approved the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director at the 41st AGM held on 23rd Sep'26. The approval complies with SEBI Regulation 17(1A) concerning directorship continuation upon reaching 75 years of age on 27th Sep'27. Mr. Ramawat holds a Bachelor's Degree in Science, brings 46 years of pharmaceutical industry experience, and has no familial relationships with existing directors or key managerial personnel.
Scruitinizer report with voting results
Annual General Meeting · 24 Sept 2026, 10:56 pm
Biofil Chemicals AGM Approves Key Resolutions and Related Party Transactions Biofil Chemicals and Pharmaceuticals announced the approval of all four resolutions at its 41st AGM held on 23rd Sep'26 with requisite majority. Shareholders approved the audited financial statements for FY26 (99.9998% in favor) and the reappointment of retiring director Mr. Smitesh Shah (99.9998% in favor). A special resolution allowing the continuation of Mr. Ashok Kumar Ramawat as Non-Executive Independent Director past 75 years of age passed unanimously with 100% approval. Additionally, material related party transactions with Cyano Pharma Private Limited secured approval with 99.9620% favorable votes.
Summary of Proceedings of 41st Annual General Meeting of the company held on Wednesday, 23rd September 2026 pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI ....
Annual General Meeting · 23 Sept 2026, 10:27 pm
Information under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 108 of the Companies Act, 2013 regarding voting through electronic ....
Annual General Meeting · 26 Aug 2026, 9:47 pm
Intimation for Dispatch of letter to those shareholders whose e-mail addresses are not registered with company/ registrar and share transfer agent/ depository participants
Others (Uncategorized) · 26 Aug 2026, 9:32 pm
Biofil Chemicals Discloses Shareholder Communication and AGM Details Biofil Chemicals and Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) via video conferencing for 3:00 PM on 23rd Sep'26. The company informed exchanges on 26th Aug'26 that it is sending letters to shareholders whose email addresses are not registered. This communication provides a web link to the FY25-26 Annual Report and AGM notice, ensuring compliance with SEBI regulations. The documents are also available on the BSE, NSE, and CDSL websites. Shareholders can request physical copies or update their details through the registrar.
Submission of Integrated Annual Report for the Financial Year 2025-26 along with Notice convening the 41st Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure ....
Others (Uncategorized) · 26 Aug 2026, 7:39 pm
Submission of Notice of 41st AGM scheduled to be held on Wednesday 23rd September 2026 at 3:00 P.M. (IST) through video conferencing (VC)/ Other audio-visual means (OAVM)
Annual General Meeting · 26 Aug 2026, 7:25 pm
Continuation of Directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-executive Independent Director of the company, notwithstanding his attaining the age of 75 (Seventy Five )Years
Change in Management · 12 Aug 2026, 12:04 am
Biofil Chemicals to Seek Shareholder Approval for Director's Continuation On 11th Aug'26, Biofil Chemicals' board approved the continuation of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-Executive Independent Director, despite his having reached the age of 75. This decision, made per SEBI LODR regulations, is now subject to shareholder approval via a Special Resolution at the upcoming 41st Annual General Meeting. Mr. Ramawat, who holds a Bachelor of Science degree and has 46 years of experience in the pharmaceuticals industry, was initially appointed on 25th Aug'20.
Un-Audited Financial Results for the quarter ended 30th June 2026
Financial Result · 11 Aug 2026, 11:47 pm
Biofil Chemicals Q1FY27 Profit Plummets 95% YoY Despite Strong Revenue Growth Biofil Chemicals reported a 95% YoY decline in Profit After Tax to ₹10.91 lakh for Q1FY27, down from ₹241.10 lakh in Q1FY26. This was despite a 92% YoY surge in Revenue from Operations to ₹12.35 crore. The profit collapse was driven by a significant rise in total expenses to ₹12.28 crore, mainly from a 709% YoY increase in the cost of materials consumed. The Pharma division posted a loss of ₹6.41 lakh, while the Chemicals division profit grew to ₹15.43 lakh. Basic EPS fell to ₹0.07 from ₹1.48 YoY.
Outcome of Board Meeting held on Tuesday 11th August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Outcome · 11 Aug 2026, 11:38 pm
Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 1,235 (+92.0% YoY | +63.2% QoQ) ■ EBITDA: 14.1 (+2324.1% YoY | -67.6% QoQ) ■ EBITDA Margin (%): 1.1 (+105 bps YoY | -461 bps QoQ) ■ PAT: 10.9 (-95.5% YoY | -48.6% QoQ) ■ EPS (INR): 0.07 (-95.3% YoY | -46.2% QoQ) Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) Segmental Performance Pharma Division ■ Revenue: 313 (-35.3% YoY | +181.1% QoQ) ■ EBIT: -6.4 (Profit to Loss YoY | +79.1% QoQ) ■ EBIT Margin (%): -2.0 (Profit to Loss YoY | +2543 bps QoQ) Chemical Division ■ Revenue: 922 (+481.4% YoY | +42.9% QoQ) ■ EBIT: 15.4 (+109.4% YoY | -78.0% QoQ) ■ EBIT Margin (%): 1.7 (-298 bps YoY | -920 bps QoQ)
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited ....
Intimation · 11 Aug 2026, 5:30 am
Biofil Chemicals Board Meeting Set for 11-Aug-26 to Approve Q1 Results Biofil Chemicals and Pharmaceuticals (NSE: BIOFILCHEM) has scheduled a Board of Directors meeting for 11-Aug-26. The primary agenda is to consider and approve the un-audited financial results for the first quarter ended 30-Jun-26. The trading window for designated persons will reopen 48 hours after the results are declared. The company will also discuss other routine matters during the meeting.
Audited Financial Result for the Financial Year ended 31.03.2026
Financial Result · 31 May 2026, 12:35 am
Biofil Chemicals Reports FY26 Results with 400% PAT Growth Driven by Asset Sale Biofil Chemicals and Pharmaceuticals reported FY26 results on 30-May'26. Full-year revenue declined 15% YoY to ₹2,839.52 lakhs, while PAT surged 400% YoY to ₹278.60 lakhs, driven by an asset disposal. For Q4FY26, revenue was ₹756.56 lakhs, down 9.4% YoY. Q4 PAT stood at ₹21.22 lakhs, up 6.3% YoY. The company noted that manufacturing was partially disrupted due to factory renovation, leading to lower turnover. The statutory auditor, Maheshwari & Gupta, issued an unmodified opinion on the annual financial results.
Outcome of Board Meeting held on Saturday 30th May, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Outcome · 31 May 2026, 12:21 am
Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 757 (-9.4% YoY | +783.5% QoQ) ■ EBITDA: 43.5 (+302.4% YoY | +358.0% QoQ) ■ EBITDA Margin (%): 5.7 (+445 bps YoY | -534 bps QoQ) ■ PAT: 21.2 (+6.3% YoY | +167.9% QoQ) ■ EPS (INR): 0.13 (+8.3% YoY | +160.0% QoQ) Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) Segmental Performance Pharma Division ■ Revenue: 111 (-79.3% YoY | +30.2% QoQ) ■ EBIT: -30.6 (-338.2% YoY | -193.1% QoQ) ■ EBIT Margin (%): -27.5 (-2618 bps YoY | -1527 bps QoQ) Chemical Division ■ Revenue: 645 (+118.2% YoY) ■ EBIT: 70.2 (+142.8% YoY | +319.3% QoQ) ■ EBIT Margin (%): 10.9 (+110 bps YoY)
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited ....
Intimation · 30 May 2026, 5:30 am
Biofil Chemicals Schedules Board Meeting for Q4 and FY26 Financial Results Biofil Chemicals and Pharmaceuticals' Board of Directors will meet on 30th May'26 to consider and approve the audited financial results for the fourth quarter and the financial year ended 31st Mar'26. The agenda includes the adoption of the Auditors' Report, Statement of Assets and Liabilities, and Cash Flow Statement. The trading window for insiders will reopen 48 hours after the results are declared.
The Company hereby submit drafts intimation letter sent to holders of Physical shares of the company for updating PAN, KYC, Nomination and other details in accordance with applicable SEBI ....
Others (Uncategorized) · 05 May 2026, 9:58 pm
Biofil Chemicals Reminds Physical Shareholders to Update KYC and Bank Details Biofil Chemicals and Pharmaceuticals, in a filing dated 05th May'26, informed shareholders holding shares in physical form of the mandatory requirement to update PAN, KYC details, bank account information, nomination, and specimen signature. This action is crucial for regulatory compliance and to ensure seamless credit of dividends and other payments. Failure to update these details restricts shareholders from availing services from the Registrar and Share Transfer Agent (RTA) and will result in receiving payments only through electronic mode from 01st Apr'24.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 10 Apr 2026, 6:14 pm
Biofil Chemicals Confirms It Is Not Classified as a Large Corporate Biofil Chemicals and Pharmaceuticals Ltd announced on 10th Apr'26 that it does not fall under the "Large Corporate" category as of 31st Mar'26. This classification exempts the company from SEBI's framework requiring mandatory fundraising through debt securities. The company reported its outstanding borrowing was ₹0.02 crore as of 31st Mar'26. Consequently, the disclosure requirements and potential penalties for shortfalls in debt issuance under the SEBI circular are not applicable to the company.
Intimation regarding SEBI Circular dated January 30, 2026-Ease of Doing Investment- Special Window for Transfer and Dematerilaisation of Physical Securities .
Others (Uncategorized) · 02 Apr 2026, 9:18 pm
Biofil Chemicals Announces Special Window for Physical Share Dematerialization Biofil Chemicals informed exchanges of a SEBI-mandated special window for transferring and dematerializing physical securities purchased before 01 Apr'19. This facility is available for one year, from 05 Feb'26 to 04 Feb'27, and also covers previously rejected or unattended transfer requests. Transferred securities will be credited in demat form and subject to a mandatory one-year lock-in period from the transfer registration date. Shareholders are directed to contact the company's Registrar and Share Transfer Agent, Ankit Consultancy Private Limited, for processing.
Un-Audited Financial Results of the Company for the quarter and nine month ended on 31st December, 2025
Financial Result · 14 Feb 2026, 12:01 am
Biofil Chemicals Q3FY26 Revenue and Profit Decline on Factory Renovation Biofil Chemicals reported a significant Q3FY26 revenue decline to ₹85.63 lakhs, down 93.9% YoY and 93.7% QoQ. The sharp fall was attributed to factory renovation disrupting manufacturing operations. Profit after tax for the quarter ended 31st Dec'25 stood at ₹7.92 lakhs, a 51.9% YoY decrease from ₹16.46 lakhs. For the nine-month period, net profit was ₹257.37 lakhs versus ₹35.81 lakhs YoY. Basic EPS for Q3FY26 was ₹0.05, down from ₹0.10 YoY. The board approved these unaudited results on 13th Feb'26.
Outcome of Board Meeting held on Friday 13th February, 2026
Outcome · 13 Feb 2026, 11:52 pm
Biofil Chemicals and Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakh) ■ Revenue: 85.6 (-94.0% YoY | -93.7% QoQ) ■ EBITDA: 9.5 (-69.1% YoY | -17.0% QoQ) ■ EBITDA Margin (%): 11.1 (+892 bps YoY | +1024 bps QoQ) ■ PAT: 7.9 (-51.9% YoY | -5.3% QoQ) ■ EPS (INR): 0.05 (-50.0% YoY | +0.0% QoQ) Biofil Chemicals and Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakh) Segmental Performance Pharma Unit ■ Revenue: 85.6 (-92.9% YoY | -92.9% QoQ) ■ EBIT: -10.5 (-346.6% YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -12.2 (-1201 bps YoY | Profit to Loss QoQ) Chemicals Division ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBIT: 16.7 (-34.2% YoY | +3537.0% QoQ) ■ EBIT Margin (%): 0.0 (-1183 bps YoY | -33 bps QoQ)
Clarification on Price Movement
Others (Uncategorized) · 04 Feb 2026, 12:39 am
Biofil Chemicals Clarifies Share Price Movement Biofil Chemicals & Pharmaceuticals, in a clarification to the BSE on 03rd Feb'26, stated there are no material developments or events within the company to justify the recent significant change in its equity share price. Management attributes the price and volume movement purely to market conditions and the prevailing stock market scenario. The company confirmed it has no pending material information to disclose under SEBI (LODR) Regulations and will promptly report any future required announcements to the exchange.
The Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Ltd on February 3, 2026 with reference to significant movement in price, in order to ensure that investors ....
Others (Uncategorized) · 03 Feb 2026, 11:47 pm
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 1. the Un-Audited ....
Intimation · 13 Feb 2026, 5:30 am
Biofil Chemicals Schedules Board Meeting for Q3 FY26 Results Biofil Chemicals and Pharmaceuticals Ltd. has scheduled a Board of Directors meeting on 13th Feb'26. The primary agenda is to consider and approve the un-audited financial results for the quarter and nine months ended 31st Dec'25. Additionally, the trading window for insiders, which was closed from 23rd Dec'25, will reopen 48 hours after the results are declared. Other routine matters will also be discussed.